利法西明加乳糖与单独的乳糖相比,降低了HE复发风险
Arun J Sanyal1, Kris V Kowdley2, Nancy S Reau3
1Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA.
Hepatology communications
|May 10, 2024
概括
利法西明加乳糖有效地减少了肝硬化患者的明显肝脑病变 (HE) 复发和住院. 这种组合疗法在各种患者亚组中显示出显著的益处.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 肝硬化患者有明显肝脑病变 (HE) 的高风险.
- 伴随性疾病,如炎和糖尿病,可以影响HE的发展和治疗的有效性.
- 根据基线特征分层对理解治疗结果至关重要.
研究的目的:
- 为了评估与单独的乳糖相比,利法西明加乳糖的疗效.
- 评估肝硬化患者的治疗有效性,这些患者有明显肝硬化风险.
- 分析基于基线特征的结果,如炎和糖尿病.
主要方法:
- 从第三阶段随机双盲试验和第四阶段开放标签试验中汇集后期小组分析.
- 成年患者每天两次服用利法西明550毫克,再加上乳糖或单独的乳糖,持续6个月.
- 分析通过关键基线特征对患者进行了分层分类.
主要成果:
- 利法西明加乳糖的疗效比单独使用乳糖的疗效更大.
- 组合疗法显著降低了明显的HE复发的风险.
- 在rifaximin加乳糖组中,与HE相关的住院病例也减少了.
结论:
- 利法西明加乳糖在预防明显的HE复发和与HE相关的住院治疗方面更有效.
- 组合治疗的好处在特定的基线疾病特征中观察到.
- 这支持rifaximin加乳糖用于管理HE风险在特定的肝硬化患者的使用.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
204
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
204
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Drugs Affecting GI Tract Motility: Other Laxatives
200
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
200
Irritable Bowel Syndrome III: Medical and Nursing Management
196
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
196


